FIELD: medicine, oncology. SUBSTANCE: method involves determination of percent content of autorosette-forming lymphocytes in blood. Occlusion is considered to be prescribed at autorosette-forming lymphocytes content from 10% to 20%. Method excludes of erythrocyte precipitation reaction from treatment schedule in part of patients. EFFECT: improved method of assay, enhanced individualization, decreased traumaticity of method. 1 dwg, 3 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOSITION FOR EMBOLIZATION OF BLOOD VESSELS | 1995 |
|
RU2073529C1 |
METHOD OF RETARDATION OF MALIGNANT TUMOR GROWTH | 1998 |
|
RU2143935C1 |
METHOD TO PREDICT RELAPSE OF SOLID TUMORS | 2001 |
|
RU2184971C1 |
METHOD FOR PREDICTING LIFE DURATION IN PATIENTS IN CASE OF ABUNDANT MALIGNANT NEOPLASMS | 2003 |
|
RU2222813C1 |
METHOD OF TREATMENT OF PARENCHYMATOUS ORGAN TUMORS | 1995 |
|
RU2065734C1 |
METHOD OF TREATMENT OF PATIENT WITH OSTEOLYTIC METASTASIS | 1999 |
|
RU2153358C1 |
METHOD FOR TREATING THE CASES OF RENAL CELL CARCINOMA | 2001 |
|
RU2179859C1 |
METHOD FOR TREATING PRIMARY OVARIAN CANCER | 2004 |
|
RU2248824C1 |
METHOD FOR TREATMENT OF PLURAL OSTEAL METASTASISES DURING MAMMARY GLAND CANCER | 2007 |
|
RU2332992C1 |
METHOD FOR TREATING THE CASES OF OVARIAN CARCINOMA RELAPSE | 2005 |
|
RU2273502C1 |
Authors
Dates
1998-08-20—Published
1997-06-03—Filed